Trinity Biotech (TRIB) Gross Margin (2016 - 2024)
Historic Gross Margin for Trinity Biotech (TRIB) over the last 16 years, with Q4 2024 value amounting to 30.76%.
- Trinity Biotech's Gross Margin fell 32500.0% to 30.76% in Q4 2024 from the same period last year, while for Dec 2024 it was 34.83%, marking a year-over-year increase of 6100.0%. This contributed to the annual value of 34.83% for FY2024, which is 6100.0% up from last year.
- Per Trinity Biotech's latest filing, its Gross Margin stood at 30.76% for Q4 2024, which was down 32500.0% from 35.03% recorded in Q3 2024.
- Over the past 5 years, Trinity Biotech's Gross Margin peaked at 52.4% during Q3 2020, and registered a low of 2.1% during Q3 2022.
- Its 5-year average for Gross Margin is 36.84%, with a median of 37.31% in 2021.
- In the last 5 years, Trinity Biotech's Gross Margin plummeted by -383500bps in 2022 and then soared by 270700bps in 2023.
- Quarter analysis of 5 years shows Trinity Biotech's Gross Margin stood at 47.79% in 2020, then decreased by -22bps to 37.08% in 2021, then decreased by -8bps to 34.18% in 2022, then dropped by 0bps to 34.01% in 2023, then decreased by -10bps to 30.76% in 2024.
- Its Gross Margin was 30.76% in Q4 2024, compared to 35.03% in Q3 2024 and 36.19% in Q2 2024.